Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2003-09-19
2010-02-16
Shultz, J D (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S069100, C435S091100, C435S091200, C435S091210, C435S091300, C435S091500, C435S091510, C435S091520, C435S183000, C435S188000, C435S193000, C536S023100, C536S024300
Reexamination Certificate
active
07662556
ABSTRACT:
The present invention provides a method of covalently joining a DNA strand to an RNA strand comprising (a) forming a topoisomerase-DNA intermediate by incubating a DNA cleavage substrate comprising a topoisomerase cleavage site with a topoisomerase specific for that site, wherein the topoisomerase-DNA intermediate has one or more 5′ single-strand tails; and (b) adding to the topoisomerase-DNA intermediate an acceptor RNA strand complementary to the 5′ single-strand tail under conditions permitting a ligation of the covalently bound DNA strand of the topoisomerase-DNA intermediate to the RNA acceptor strand and dissociation of the topoisomerase, thereby covalently joining the DNA strand to the RNA strand. The present invention also provides a method of tagging a 5′ end of an RNA molecule. The present invention further provides a DNA-RNA molecule which has been joined in vitro by the use of a topoisomerase. The present invention also provides a method of tagging a 5′ end of an mRNA. The present invention provides a method of isolating and cloning full-length gene sequences using capped mRNA after subtraction of non-capped RNA.
REFERENCES:
patent: 4661450 (1987-04-01), Kempe et al.
patent: 4800159 (1989-01-01), Mullis et al.
patent: 5624826 (1997-04-01), Kato et al.
patent: 5746997 (1998-05-01), Reed
patent: 5766891 (1998-06-01), Shuman et al.
patent: 6238884 (2001-05-01), Short et al.
patent: 6280977 (2001-08-01), Liang et al.
patent: 6291213 (2001-09-01), Rothstein
patent: 6548277 (2003-04-01), Shuman et al.
patent: 6653106 (2003-11-01), Shuman et al.
patent: 0373914 (1994-04-01), None
patent: 0625572 (2001-04-01), None
patent: WO8504898 (1985-11-01), None
patent: WO9429443 (1994-12-01), None
patent: WO9619497 (1996-06-01), None
patent: WO9634981 (1996-11-01), None
patent: WO9724455 (1997-07-01), None
patent: WO9820122 (1998-05-01), None
patent: WO9855502 (1998-12-01), None
patent: WO9856943 (1998-12-01), None
patent: WO0012687 (2000-03-01), None
patent: WO0056878 (2000-09-01), None
patent: WO0162892 (2001-08-01), None
patent: WO0162943 (2001-08-01), None
patent: WO0216594 (2002-02-01), None
Shuman, Novel approaches to Molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase, 1994, J. Biol. chem., 269, 32678-32684.
Chenchick et al, Full length cDNA cloning and determination of mRNA 5′ and 3′ ends by amplification of adaptor ligated cDNA, 1996, Biotechniques, 21, 526-534.
Schaefer, Revolutions in rapid amplification of cDNA ends. New strategies for polymerase chain reaction cloning of full length cDNA ends., 1995, Ananlytical Biochemistry, 227, 255-273.
Arnott et al. “DNA-RNA hybrid secondary structures,” J. Mol. Biol. 188(4):631-640 (1986).
Carninci et al. “High efficiency selection of full-length cDNA by improved biotinylated cap trapper,” DNA Research 4:61-66 (1997).
Carninci et al. “High-efficiency full-length cDNA cloning by biotinylated CAP trapper,” Genomics 37(3):327-36 (1996).
Cheng and Shuman, “A catalytic domain of eukaryotic DNA topoisomerase I,” J. Biol. Chem. 273(19):115898-95 (1998).
Cheng and Shuman, “DNA strand transfer catalyzed by vaccinia topoisomerase: ligation of DNAs containing a 3′ mononucleotide overhang,” Nucleic Acids Res. 28(9):1893-8 (2000).
Cheng and Shuman, “Recombinogenic flap ligation pathway for intrinsic repair of topoisomerase IB-induced double-strand breaks,” Mol. Cell. Biol. 20(21):8059-8068 (2000).
Cheng and Shuman, “Site-specific DNA transesterification by vaccinia topoisomerase: Role of specific phosphates and nucleosides,” Biochemistry 38(50):16599-612 (1999).
Cheng et al. “Conservation of structure and mechanism between eukaryotic topoisomerase I and site-specific recombinases,” Cell 92(6):841-50 (1998).
Cheng et al. “Mutational analysis of 39 residues of vaccinia DNA topoisomerase identifies Lys-220, Arg-223, and Asn-228 as important for covalent catalysis,” J. Biol. Chem. 272(13):8263-9 (1997).
Chong S. et al. “Single-column purification of free recombinant proteins using a self-cleavable affinity tag derived from a protein splicing element,” Gene 192(2):271-281 (1997).
DiGate and Marians, “Molecular cloning and DNA sequence analysis ofEscherichia colitopoB, the gene encoding topoisomerase III,” J. Biol. Chem. 264(30):17924-17930 (1989).
Edery et al. “An efficient strategy to isolate full-length cDNAs based on an mRNA cap retention procedure (CAPture),” Mol. Cell. Biol. 15(6):3363-3371 (1995).
Ericsson et al. “Characterization of ts16, a temperature-sensitive mutant of vaccinia virus,” J. Virol. 69(11):7072-86 (1995).
Gross and Shuman, “Vaccinia virions lacking the RNA helicase nucleoside triphosphate phosphohydrolase II are defective in early transcription,” J. Virol. 70(12):8549-5 (1996).
Haghighat and Sonenberg, “eIF4G dramatically enhances the binding of eIF4E to the mRNA 5′-cap structure,” J. Biol. Chem. 272(35):21677-21680 (1997).
Haghighat et al. “The eIF4G-eIF4E complex is the target for direct cleavage by the rhinovirus 2A proteinase,” J. Virol. 70:8444-8450 (1996).
Henningfeld and Hecht, “A model for topoisomerase I-mediated insertions and deletions with duplex DNA substrates containing branches, nicks, and gaps,” Biochemistry 34(18):6120-9 (1995).
Invitrogen Corporation, Carlsbad, California, catalog pp. 18, 29, 43, 44, 49-52 (1998).
Janknecht et al. “Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus,” Proc. Natl. Acad. Sci. U.S.A. 88:8972-8976(1991).
Kane and Shuman, “Vaccinia virus morphogenesis is blocked by a temperature-sensitive mutation in the 17 gene that encodes a virion component,” J. Virol. 67(5):2689-98 (1993).
Kato et al. “Construction of a human full-length cDNA bank,” Gene 150:243-250 (1994).
Klemm et al. “Peptide inhibitors of DNA cleavage by tyrosine recombinases and topoisomerases,” J. Mol. Biol. 299(5):1203-16 (2000).
Klemperer et al. “Identification and characterization of the orf virus type 1 topoisomerase,” Virology 206:203-215 (1995).
Krogh and Shuman, “Catalytic mechanism of DNA topoisomerase IB,” Mol. Cell 5(6):1035-41 (2000).
Krogh and Shuman, “DNA strand transfer catalyzed by vaccinia topoisomerase: peroxidolysis and hydroxylaminolysis of the covalent protein-DNA intermediate,” Biochemistry 39(21):6422-32 (2000).
Krogh and Shuman, “Vaccinia topoisomerase mutants illuminate conformational changes during closure of the protein clamp and assembly of a functional active site,” J. Biol. Chem. 276:36091-99 (2001).
Krogh et al. “Effect of 2′-5′ phosphodiesters on DNA transesterification by vaccinia topoisomerase,” J. Biol. Chem. 276(24):20907-20912 (2001).
Krogh et al. “Melanoplus sanguinipes entomopoxvirus DNA topoisomerase: site-specific DNA transesterification and effects of 5′-bridging phosphorothiolates,” Virology 264(2):441-51 (1999).
Liu et al. “Mapping the 5′ and 3′ ends of tetrahymena thermophila mRNAs using ligase mediated amplification of cDNA ends (RLM-RACE),” Nucleic Acids Res. 21(21):4954-4960 (1993).
Lockard et al. “Labeling of eukaryotic messenger RNA 5′ terminus with phosphorus-32: Use of tobacco acid pyrophosphatase for removal of cap structure,” Gene Amp. Anal. 2:229-251 (1981).
Maruyama et al. “Oligo-Capping: A simple method to replace the cap structure of eukaryotic mRNAs with oligonucleotides,” Gene 138:171-174 (1994).
Matthews et al. “Analytical strategies for the use of DNA probes,” Anal. Biochem. 169:1-25 (1988).
Morham and Shuman, “Covalent and noncovalent DNA binding by mutants of vaccinia DNA topoisomerase I,” J. Biol. Chem. 267:15984-15992 (1992).
Morham and S
Comiskey John
Fernandez Joseph
Hoeffler James
Marcil Robert
Sekiguchi JoAnn
Bhat Narayan K
Cooper & Dunham LLP
Shultz J D
Sloan Kettering Institute for Cancer Research
White John P.
LandOfFree
Covalent joining of DNA to RNA by vaccinia topoisomerase and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Covalent joining of DNA to RNA by vaccinia topoisomerase and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Covalent joining of DNA to RNA by vaccinia topoisomerase and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4203074